This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/531716-china-vaccination-covid19-sinovac/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| China administers 1.8 billion Covid vaccines as Sinovac says third shot delivers big increase in immunity | China administers 1.8 billion Covid vaccines as Sinovac says third shot delivers big increase in immunity |
| (about 2 months later) | |
| The Chinese authorities have hit a new milestone, administering 1.8 billion vaccines in the fight against Covid-19, as shot-maker Sinovac says efficacy concerns can be overcome using a third jab. | The Chinese authorities have hit a new milestone, administering 1.8 billion vaccines in the fight against Covid-19, as shot-maker Sinovac says efficacy concerns can be overcome using a third jab. |
| On Wednesday, China’s National Health Commission said that a total of 1.808 billion vaccines had been administered in the country, after 13 million doses were given on Tuesday. | On Wednesday, China’s National Health Commission said that a total of 1.808 billion vaccines had been administered in the country, after 13 million doses were given on Tuesday. |
| Although a breakdown of first and second shots is not available, the number of jabs administered is roughly enough to cover around 65% of the country’s 1.4 billion people. | Although a breakdown of first and second shots is not available, the number of jabs administered is roughly enough to cover around 65% of the country’s 1.4 billion people. |
| The milestone comes as Chinese vaccine-makers Sinovac said that a third dose of their CoronaVac shot substantially increased antibody levels during trials. | The milestone comes as Chinese vaccine-makers Sinovac said that a third dose of their CoronaVac shot substantially increased antibody levels during trials. |
| The study, which was published on Sunday in medRvix, stated that patients who received a 3 microgram third dose saw a seven-fold increase in antibody levels compared to the levels recorded 28 days after the second dose. | The study, which was published on Sunday in medRvix, stated that patients who received a 3 microgram third dose saw a seven-fold increase in antibody levels compared to the levels recorded 28 days after the second dose. |
| The scientists noted that antibody levels “declined substantially” six months after two doses, suggesting a third shot may be necessary. | The scientists noted that antibody levels “declined substantially” six months after two doses, suggesting a third shot may be necessary. |
| In a statement sent to the Global Times on Monday, Sinovac said the study will provide important information to policymakers concerning plans for booster shots. | In a statement sent to the Global Times on Monday, Sinovac said the study will provide important information to policymakers concerning plans for booster shots. |
| The vaccine’s efficacy has been questioned in recent months after several studies and real-world data suggested its performance wasn’t matching up with clinical trial data. A Thai study suggested that vaccine-induced antibodies halved every 40 days after the second dose. | The vaccine’s efficacy has been questioned in recent months after several studies and real-world data suggested its performance wasn’t matching up with clinical trial data. A Thai study suggested that vaccine-induced antibodies halved every 40 days after the second dose. |
| China’s medical regulator has approved a trial to combine the Sinovac shot with a DNA vaccine developed by American biotech company Inovio, the company’s boss said on Tuesday. The trial is due to begin in the autumn. | China’s medical regulator has approved a trial to combine the Sinovac shot with a DNA vaccine developed by American biotech company Inovio, the company’s boss said on Tuesday. The trial is due to begin in the autumn. |
| If you like this story, share it with a friend! | If you like this story, share it with a friend! |